<DOC>
	<DOCNO>NCT00246025</DOCNO>
	<brief_summary>The goal study evaluate comparative efficacy safety three different dos ( 110 mg , 150 mg , 220 mg ) BIBR 1048 ( Dabigatran etexilate ) orally , compare placebo , prevention venous thromboembolism patient primary elective total knee replacement surgery , evaluate dose-response .</brief_summary>
	<brief_title>A Study BIBR 1048 Prevention Venous Thromboembolism Patients With TKR Surgery .</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion Inclusion criterion 1 . Patients schedule undergo primary , unilateral elective total knee replacement 2 . Male Female 20 year age order 3 . Patients weigh least 40 kg 4 . Written inform consent prior start study participation Exclusion criterion Exclusion criterion 1 . History bleed diathesis 2 . Constitutional acquire coagulation disorder investigator 's judgment put patient excessive risk bleed 3 . Major surgery trauma ( e.g . hip fracture ) within last 3 month 4 . Recent unstable cardiovascular disease , uncontrolled hypertension time enrollment ( investigator 's judgment ) history myocardial infarction within last 3 month 5 . Any history hemorrhagic stroke follow intracranial pathology : bleeding , neoplasm , AV ( arteriovenous ) malformation aneurysm recent bleed history 6 . Condition require anticoagulant therapy 7 . Elevated AST ( Aspartate Aminotransferase ) , ALT ( Alanine Aminotransferase ) , history clinically relevant liver disease 8 . Patients history clinically significant renal disease elevate creatinine value</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>